AstraZeneca's 'Clear-Out' Strategy Sees Gout Drug Go To Grunenthal

AstraZeneca is licensing its unlaunched gout drug Zurampic (lesinurad) out to privately held Grunenthal for sale in Europe and Latin America in the UK pure pharma's latest divesture of non-core assets amid efforts to focus on its central activities while also unlocking value from medicines in its portfolio.